Innocan Pharma Corporation

Recent News

  • Innocan Phrama Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) CBD Premium Facial Serum on Skin Hydration

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 15, 2020) -   Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce today, that it has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol ("CBD") (the "Serum") on skin hydration.

    2020-09-15 4:00 PM ET
  • Innocan Pharma to Amend Warrants Held by Tamar Technologies Ltd.

    Toronto, Ontario--(Newsfile Corp. - September 14, 2020) - Innocan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), announces that its board of directors has agreed to amend the terms of certain common share purchase warrants (the "Warrants") held by Tamar Innovest Ltd. (formerly, Solsken Ltd.) ("Tamar").The Warrants were issued by the Company on April 15, 2019 and consist of: (a) 13,981,916 Warrants at an exercise price of US $0.1252 expiring April 15, 2021 pursuant to Warrant Certificate No....

    2020-09-14 4:00 PM ET
  • Innocan Pharma Announces Publication of Enterprise Report by Mackie Research

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that Mackie Research Capital Corporation's institutional sales group has issued an updated Enterprise report on the Company. The Enterprise report provides valuable insight into companies that embody value-add for investors, have distinguished themselves among their peers and are bringing innovative and creative ideas into action. Mackie Research's analyst, Yue (Toby) Ma, Ph.D., indicates...

    2020-09-03 3:08 AM ET
  • Innocan to Distribute Its CBD Line of Products in Italy and Switzerland

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 20, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a distribution agreement (the "Agreement") with a Swiss CBD provider called Cloud 9 Switzerland LLC ("Cloud 9") to sell the Company's SHIRTM Beauty and Relief & Go product lines in Italy and Switzerland.Under the terms of the Agreement, Cloud 9...

    2020-08-20 4:00 PM ET
  • Innocan Engages Endless Sky to Manufacture and Distribute Innocan's CBD Cosmetic Products in Canada

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its wholly owned subsidiary, Innocan Pharma Ltd. ("Innocan Israel") has entered into a manufacturing and distribution agreement (the "Agreement") with Endless Sky Incorporated ("ESI"), a Canadian large scale Cannabis extractor based in Calgary, Alberta.Under the Agreement, ESI will serve as the exclusive distributor of Innocan's CBD products in Canada under a license granted...

    2020-08-11 4:00 PM ET
  • Innocan's SHIR (TM) Beauty & Science CBD Derma Cosmetics Products Passed Safety Assessments and Have Been Approved for Marketing in the European Union

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 6, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union. SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an...

    2020-08-06 4:31 PM ET
  • Innocan's Over-The-Counter Pain Relief Spray Receives FDA's Technical Validation for Marketing in the USA

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 13, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it has received notice from the FDA that Innocan's over-the-counter Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA. Innocan's pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD. The Relief & GO Pain Relief spray is...

    2020-07-13 2:00 AM ET
  • InnoCan Pharma Collaborate with Recipharm on its CBD Loaded Exosome (CLX) Treatments

    Herzeliya, Israel and Calgary, Alberta--(Newsfile Corp. - July 9, 2020) - InnoCan Pharma Corporation (CNSX: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce its collaboration with Recipharm, Israel to synthesize and analyze cannabinoid loaded exosomes.Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas, pharmaceutical development services and manufacturing services. Recipharm offers seamless tech transfer from Recipharm development facilities and provide commercial supply of a...

    2020-07-09 3:00 AM ET